Spatial and Temporal Characterization of Gliomas Using Radiomic Analysis (GLIO-RAD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Dr. ARCHYA DASGUPTA, MD
- Phone Number: 6861 022-24177000
- Email: archya1010@gmail.com
Study Locations
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400012
- Recruiting
- Tata Memorial Hospital
-
Contact:
- Dr Archya Dasgupta, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with glioma or glioma-mimicking pathology with imaging available in TMC between January 2010 and December 2022.
Exclusion Criteria:
- Imaging done outside TMC.
- Motion artifacts or other artifacts causing image degradation.
- Size of tumor or region of interest < 1 cm in the largest dimension
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Autosegmentation of tumor
Time Frame: 3 years
|
The correlation of tumor region between manual segmentation and artificial intelligence-based autosegmentation model will be assessed using the Dice coefficient of similarity.
|
3 years
|
|
Prognostication of gliomas
Time Frame: 3 years
|
Radiomic signature in prognostication of gliomas with estimation of progression-free survival and overall survival using Kaplan Meier plots and radiomics score-based nomograms.
|
3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Response assessment in gliomas
Time Frame: 3 years
|
Response assessment of gliomas using artificial intelligence model-based prediction and comparison with actual response (like radionecrosis, progression) using confusion matrices and estimation of parameters like sensitivity, specificity, accuracy, area under curve.
|
3 years
|
|
Differentiation of glioma from non-glioma histology
Time Frame: 3 years
|
Use of radiomics model to differentiate gliomas from other brain tumors, with performance indices calculated using sensitivity, specificity, accuracy, area under curve.
|
3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Dr. ARCHYA DASGUPTA, MD, Tata Memorial Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 4146
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.